This Phase I study provides the first detailed human pharmacokinetic characterisation of intravenous DMT fumarate (SPL026), demonstrating dose‑proportional exposure across 9–21.5 mg, rapid peak plasma concentrations (~10 min), a short elimination half‑life (9–12 min), ~70% unbound fraction and good tolerability. In vitro data indicate mitochondrial MAO‑A‑mediated metabolism with modulation by CYP2D6 and CYP2C19, supporting the design of DMT infusion regimens for major depressive disorder.
- Published
- Journal
- European Journal of Pharmacology
- Authors
- Good, M., Joel, Z., Benway, T., Routledge, C., Timmermann, C., Erritzoe, D., Weaver, R., Allen, G., Hughes, C., Topping, H., Bowman, A., James, E.